Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria
Authors:
- Marcus V.G. LacerdaMLMarcus V.G. Lacerda
- Alejandro Llanos-CuentasALAlejandro Llanos-Cuentas
- Srivicha KrudsoodSKSrivicha Krudsood
- Chanthap LonCLChanthap Lon
- David L. SaundersDSDavid L. Saunders
- Rezika MohammedRMRezika Mohammed
- Daniel YilmaDYDaniel Yilma
- Dhelio Batista PereiraDPDhelio Batista Pereira
- Fe E.J. EspinoFEFe E.J. Espino
- Reginaldo Z. MiaRMReginaldo Z. Mia
- Raul ChuquiyauriRCRaul Chuquiyauri
- Fernando ValFVFernando Val
Top Cited Papers
Open Access
- 17 January 2019
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (3) , 215-228
Abstract
Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed “radical cure”). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax. This multicenter, double-blind, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines. We enrolled 522 patients with microscopically confirmed P. vivax infection (>100 to P. vivax clearance without recurrent parasitemia. In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 months was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1). The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (PP. vivax recurrence than placebo in patients with phenotypically normal G6PD activity. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167.)Keywords
Funding Information
- Medicines for Malaria Venture
- GlaxoSmithKline
This publication has 32 references indexed in Scilit:
- Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicityProceedings of the National Academy of Sciences, 2013
- The metabolism of primaquine to its active metabolite is dependent on CYP 2D6Malaria Journal, 2013
- G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based MapPLOS Medicine, 2012
- Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon RegionMalaria Journal, 2011
- Confirmed Vivax Resistance to Chloroquine and Effectiveness of Artemether-Lumefantrine for the Treatment of Vivax Malaria in EthiopiaThe American Journal of Tropical Medicine and Hygiene, 2011
- Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantificationBiomedical Chromatography, 2010
- Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar borderMalaria Journal, 2010
- Evaluation ofPlasmodium vivaxGenotyping Markers for Molecular Monitoring in Clinical TrialsThe Journal of Infectious Diseases, 2009
- A comprehensive study on the major mutations in glucose-6-phosphate dehydrogenase-deficient polymorphic variants identified in the coastal provinces of Caspian Sea in the north of IranClinical Biochemistry, 2007
- Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in the south of Thailand and identification of a novel variant (G6PD Songklanagarind)Blood Cells, Molecules, and Diseases, 2005